Trial Outcomes & Findings for Optimization and Multi-Site Feasibility of Yoga for Chronic Pain in People in YOGAMAT-II - Phase II (NCT NCT04641221)
NCT ID: NCT04641221
Last Updated: 2025-11-20
Results Overview
Total minutes per week practicing yoga, including in class and outside of class, assessed weekly via interview
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
192 participants
Primary outcome timeframe
3 months
Results posted on
2025-11-20
Participant Flow
For these purposes, we defined completion as completing the BPI at Month 3 or Month 12
Participant milestones
| Measure |
No Video/No One-on-One/No Text/No Incentive
This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes
|
No Video/No One-on-One/No Text/Yes Incentive
This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, but DOES receive financial Incentives to attend yoga classes
|
No Video/No One-on-One/Yes Text/No Incentive
This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or financial Incentives to attend yoga classes, but DOES receive prompting Text messages
|
No Video/No One-on-One/Yes Text/Yes Incentive
This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, but DOES receive prompting Text messages and financial Incentives to attend yoga classes
|
No Video/Yes One-on-One/No Text/No Incentive
This group does not receive Personal Practice Videos or prompting Text messages or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor
|
No Video/Yes One-on-One/No Text/Yes Incentive
This group does not receive Personal Practice Videos or prompting Text messages, but DOES receive One-on-One individual sessions with a Yoga Instructor, and financial Incentives to attend yoga classes
|
No Video/Yes One-on-One/Yes Text/No Incentive
This group does not receive Personal Practice Videos or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor and prompting Text messages
|
No Video/Yes One-on-One/Yes Text/Yes Incentive
This group does not receive Personal Practice Videos, but DOES receive One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
|
Yes Video/No One-on-One/No Text/No Incentive
This group does not receive One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos
|
Yes Video/No One-on-One/No Text/Yes Incentive
This group does not receive One-on-One individual sessions with a Yoga Instructor or prompting Text messages, but DOES receive Personal Practice Videos and financial Incentives to attend yoga classes
|
Yes Video/No One-on-One/Yes Text/No Incentive
This group does not receive One-on-One individual sessions with a Yoga Instructor or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos and prompting Text messages
|
Yes Video/No One-on-One/Yes Text/Yes Incentive
This group does not receive One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos, prompting Text messages, and financial Incentives to attend yoga classes
|
Yes Video/Yes One-on-One/No Text/No Incentive
This group does not receive prompting Text messages or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos and One-on-One individual sessions with a Yoga Instructor
|
Yes Video/Yes One-on-One/No Text/Yes Incentive
This group does not receive prompting Text messages, but DOES receive Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, and financial Incentives to attend yoga classes
|
Yes Video/Yes One-on-One/Yes Text/No Incentive
This group does not receive financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor and prompting Text messages
|
Yes Video/Yes One-on-One/Yes Text/Yes Incentive
This group receives Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
First 3 months
STARTED
|
12
|
12
|
12
|
12
|
12
|
12
|
12
|
12
|
12
|
12
|
12
|
12
|
12
|
12
|
12
|
12
|
|
First 3 months
COMPLETED
|
10
|
11
|
9
|
9
|
9
|
12
|
7
|
11
|
6
|
9
|
10
|
6
|
8
|
8
|
5
|
8
|
|
First 3 months
NOT COMPLETED
|
2
|
1
|
3
|
3
|
3
|
0
|
5
|
1
|
6
|
3
|
2
|
6
|
4
|
4
|
7
|
4
|
|
All 12 months
STARTED
|
12
|
12
|
12
|
12
|
12
|
12
|
12
|
12
|
12
|
12
|
12
|
12
|
12
|
12
|
12
|
12
|
|
All 12 months
COMPLETED
|
10
|
11
|
9
|
8
|
6
|
10
|
7
|
8
|
5
|
9
|
8
|
10
|
6
|
9
|
7
|
9
|
|
All 12 months
NOT COMPLETED
|
2
|
1
|
3
|
4
|
6
|
2
|
5
|
4
|
7
|
3
|
4
|
2
|
6
|
3
|
5
|
3
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Optimization and Multi-Site Feasibility of Yoga for Chronic Pain in People in YOGAMAT-II - Phase II
Baseline characteristics by cohort
| Measure |
No Video/No One-on-One/No Text/No Incentive
n=12 Participants
This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes
|
No Video/No One-on-One/No Text/Yes Incentive
n=12 Participants
This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, but DOES receive financial Incentives to attend yoga classes
|
No Video/No One-on-One/Yes Text/No Incentive
n=12 Participants
This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or financial Incentives to attend yoga classes, but DOES receive prompting Text messages
|
No Video/No One-on-One/Yes Text/Yes Incentive
n=12 Participants
This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, but DOES receive prompting Text messages and financial Incentives to attend yoga classes
|
No Video/Yes One-on-One/No Text/No Incentive
n=12 Participants
This group does not receive Personal Practice Videos or prompting Text messages or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor
|
No Video/Yes One-on-One/No Text/Yes Incentive
n=12 Participants
This group does not receive Personal Practice Videos or prompting Text messages, but DOES receive One-on-One individual sessions with a Yoga Instructor, and financial Incentives to attend yoga classes
|
No Video/Yes One-on-One/Yes Text/No Incentive
n=12 Participants
This group does not receive Personal Practice Videos or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor and prompting Text messages
|
No Video/Yes One-on-One/Yes Text/Yes Incentive
n=12 Participants
This group does not receive Personal Practice Videos, but DOES receive One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
|
Yes Video/No One-on-One/No Text/No Incentive
n=12 Participants
This group does not receive One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos
|
Yes Video/No One-on-One/No Text/Yes Incentive
n=12 Participants
This group does not receive One-on-One individual sessions with a Yoga Instructor or prompting Text messages, but DOES receive Personal Practice Videos and financial Incentives to attend yoga classes
|
Yes Video/No One-on-One/Yes Text/No Incentive
n=12 Participants
This group does not receive One-on-One individual sessions with a Yoga Instructor or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos and prompting Text messages
|
Yes Video/No One-on-One/Yes Text/Yes Incentive
n=12 Participants
This group does not receive One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos, prompting Text messages, and financial Incentives to attend yoga classes
|
Yes Video/Yes One-on-One/No Text/No Incentive
n=12 Participants
This group does not receive prompting Text messages or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos and One-on-One individual sessions with a Yoga Instructor
|
Yes Video/Yes One-on-One/No Text/Yes Incentive
n=12 Participants
This group does not receive prompting Text messages, but DOES receive Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, and financial Incentives to attend yoga classes
|
Yes Video/Yes One-on-One/Yes Text/No Incentive
n=12 Participants
This group does not receive financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor and prompting Text messages
|
Yes Video/Yes One-on-One/Yes Text/Yes Incentive
n=12 Participants
This group receives Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
|
Total
n=192 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
44.8 Years
STANDARD_DEVIATION 11.7
|
43.0 Years
STANDARD_DEVIATION 8.6 • n=4 Participants
|
41.8 Years
STANDARD_DEVIATION 8.1 • n=8 Participants
|
45.7 Years
STANDARD_DEVIATION 8.9 • n=19 Participants
|
43.1 Years
STANDARD_DEVIATION 10.1 • n=254 Participants
|
47.0 Years
STANDARD_DEVIATION 13.5 • n=406 Participants
|
43.8 Years
STANDARD_DEVIATION 11.0 • n=24 Participants
|
47.2 Years
STANDARD_DEVIATION 10.4 • n=94 Participants
|
42.4 Years
STANDARD_DEVIATION 8.9 • n=12 Participants
|
49.4 Years
STANDARD_DEVIATION 10.5 • n=3 Participants
|
39.9 Years
STANDARD_DEVIATION 9.7 • n=3 Participants
|
45.8 Years
STANDARD_DEVIATION 11.2 • n=3 Participants
|
43.2 Years
STANDARD_DEVIATION 9.5 • n=3 Participants
|
43.9 Years
STANDARD_DEVIATION 10.6 • n=11 Participants
|
48.0 Years
STANDARD_DEVIATION 10.8 • n=3 Participants
|
48.4 Years
STANDARD_DEVIATION 12.0 • n=3 Participants
|
44.8 Years
STANDARD_DEVIATION 10.4 • n=7 Participants
|
|
Sex: Female, Male
Female
|
7 Participants
|
6 Participants
n=4 Participants
|
7 Participants
n=8 Participants
|
9 Participants
n=19 Participants
|
11 Participants
n=254 Participants
|
6 Participants
n=406 Participants
|
6 Participants
n=24 Participants
|
8 Participants
n=94 Participants
|
10 Participants
n=12 Participants
|
6 Participants
n=3 Participants
|
10 Participants
n=3 Participants
|
8 Participants
n=3 Participants
|
10 Participants
n=3 Participants
|
5 Participants
n=11 Participants
|
7 Participants
n=3 Participants
|
8 Participants
n=3 Participants
|
124 Participants
n=7 Participants
|
|
Sex: Female, Male
Male
|
5 Participants
|
6 Participants
n=4 Participants
|
5 Participants
n=8 Participants
|
3 Participants
n=19 Participants
|
1 Participants
n=254 Participants
|
6 Participants
n=406 Participants
|
6 Participants
n=24 Participants
|
4 Participants
n=94 Participants
|
2 Participants
n=12 Participants
|
6 Participants
n=3 Participants
|
2 Participants
n=3 Participants
|
4 Participants
n=3 Participants
|
2 Participants
n=3 Participants
|
7 Participants
n=11 Participants
|
5 Participants
n=3 Participants
|
4 Participants
n=3 Participants
|
68 Participants
n=7 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=254 Participants
|
1 Participants
n=406 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=94 Participants
|
0 Participants
n=12 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=11 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=254 Participants
|
0 Participants
n=406 Participants
|
0 Participants
n=24 Participants
|
1 Participants
n=94 Participants
|
0 Participants
n=12 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=11 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
|
2 Participants
n=4 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=19 Participants
|
0 Participants
n=254 Participants
|
0 Participants
n=406 Participants
|
1 Participants
n=24 Participants
|
0 Participants
n=94 Participants
|
0 Participants
n=12 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=3 Participants
|
1 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=11 Participants
|
1 Participants
n=3 Participants
|
1 Participants
n=3 Participants
|
8 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Black or African American
|
1 Participants
|
2 Participants
n=4 Participants
|
2 Participants
n=8 Participants
|
1 Participants
n=19 Participants
|
1 Participants
n=254 Participants
|
1 Participants
n=406 Participants
|
1 Participants
n=24 Participants
|
0 Participants
n=94 Participants
|
0 Participants
n=12 Participants
|
2 Participants
n=3 Participants
|
1 Participants
n=3 Participants
|
2 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=11 Participants
|
2 Participants
n=3 Participants
|
2 Participants
n=3 Participants
|
19 Participants
n=7 Participants
|
|
Race (NIH/OMB)
White
|
10 Participants
|
7 Participants
n=4 Participants
|
9 Participants
n=8 Participants
|
9 Participants
n=19 Participants
|
9 Participants
n=254 Participants
|
10 Participants
n=406 Participants
|
8 Participants
n=24 Participants
|
10 Participants
n=94 Participants
|
12 Participants
n=12 Participants
|
8 Participants
n=3 Participants
|
9 Participants
n=3 Participants
|
7 Participants
n=3 Participants
|
9 Participants
n=3 Participants
|
11 Participants
n=11 Participants
|
9 Participants
n=3 Participants
|
9 Participants
n=3 Participants
|
146 Participants
n=7 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
|
1 Participants
n=4 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=19 Participants
|
1 Participants
n=254 Participants
|
0 Participants
n=406 Participants
|
2 Participants
n=24 Participants
|
1 Participants
n=94 Participants
|
0 Participants
n=12 Participants
|
2 Participants
n=3 Participants
|
1 Participants
n=3 Participants
|
2 Participants
n=3 Participants
|
2 Participants
n=3 Participants
|
0 Participants
n=11 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
13 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=19 Participants
|
1 Participants
n=254 Participants
|
0 Participants
n=406 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=94 Participants
|
0 Participants
n=12 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=3 Participants
|
0 Participants
n=11 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
4 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
1 Participants
|
2 Participants
n=4 Participants
|
3 Participants
n=8 Participants
|
1 Participants
n=19 Participants
|
0 Participants
n=254 Participants
|
0 Participants
n=406 Participants
|
1 Participants
n=24 Participants
|
1 Participants
n=94 Participants
|
1 Participants
n=12 Participants
|
2 Participants
n=3 Participants
|
2 Participants
n=3 Participants
|
1 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=11 Participants
|
2 Participants
n=3 Participants
|
1 Participants
n=3 Participants
|
19 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
11 Participants
|
10 Participants
n=4 Participants
|
9 Participants
n=8 Participants
|
11 Participants
n=19 Participants
|
12 Participants
n=254 Participants
|
12 Participants
n=406 Participants
|
11 Participants
n=24 Participants
|
11 Participants
n=94 Participants
|
11 Participants
n=12 Participants
|
10 Participants
n=3 Participants
|
10 Participants
n=3 Participants
|
11 Participants
n=3 Participants
|
12 Participants
n=3 Participants
|
11 Participants
n=11 Participants
|
10 Participants
n=3 Participants
|
11 Participants
n=3 Participants
|
173 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=254 Participants
|
0 Participants
n=406 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=94 Participants
|
0 Participants
n=12 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=11 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=7 Participants
|
|
Region of Enrollment
United States · Rhode Island
|
3 Participants
|
2 Participants
n=4 Participants
|
6 Participants
n=8 Participants
|
7 Participants
n=19 Participants
|
4 Participants
n=254 Participants
|
7 Participants
n=406 Participants
|
4 Participants
n=24 Participants
|
4 Participants
n=94 Participants
|
5 Participants
n=12 Participants
|
5 Participants
n=3 Participants
|
6 Participants
n=3 Participants
|
5 Participants
n=3 Participants
|
5 Participants
n=3 Participants
|
5 Participants
n=11 Participants
|
3 Participants
n=3 Participants
|
5 Participants
n=3 Participants
|
76 Participants
n=7 Participants
|
|
Region of Enrollment
United States · Massachusetts
|
9 Participants
|
10 Participants
n=4 Participants
|
5 Participants
n=8 Participants
|
5 Participants
n=19 Participants
|
8 Participants
n=254 Participants
|
3 Participants
n=406 Participants
|
8 Participants
n=24 Participants
|
8 Participants
n=94 Participants
|
6 Participants
n=12 Participants
|
7 Participants
n=3 Participants
|
6 Participants
n=3 Participants
|
7 Participants
n=3 Participants
|
7 Participants
n=3 Participants
|
6 Participants
n=11 Participants
|
9 Participants
n=3 Participants
|
6 Participants
n=3 Participants
|
110 Participants
n=7 Participants
|
|
Region of Enrollment
United States · Ohio
|
0 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=254 Participants
|
2 Participants
n=406 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=94 Participants
|
1 Participants
n=12 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=11 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=3 Participants
|
6 Participants
n=7 Participants
|
|
Medication for Addiction Treatment
Methadone
|
7 Participants
|
3 Participants
n=4 Participants
|
5 Participants
n=8 Participants
|
8 Participants
n=19 Participants
|
5 Participants
n=254 Participants
|
8 Participants
n=406 Participants
|
6 Participants
n=24 Participants
|
8 Participants
n=94 Participants
|
7 Participants
n=12 Participants
|
5 Participants
n=3 Participants
|
6 Participants
n=3 Participants
|
6 Participants
n=3 Participants
|
5 Participants
n=3 Participants
|
6 Participants
n=11 Participants
|
6 Participants
n=3 Participants
|
5 Participants
n=3 Participants
|
96 Participants
n=7 Participants
|
|
Medication for Addiction Treatment
Buprenorphine
|
5 Participants
|
9 Participants
n=4 Participants
|
7 Participants
n=8 Participants
|
4 Participants
n=19 Participants
|
7 Participants
n=254 Participants
|
4 Participants
n=406 Participants
|
6 Participants
n=24 Participants
|
4 Participants
n=94 Participants
|
5 Participants
n=12 Participants
|
7 Participants
n=3 Participants
|
6 Participants
n=3 Participants
|
6 Participants
n=3 Participants
|
7 Participants
n=3 Participants
|
6 Participants
n=11 Participants
|
6 Participants
n=3 Participants
|
7 Participants
n=3 Participants
|
96 Participants
n=7 Participants
|
PRIMARY outcome
Timeframe: 3 monthsTotal minutes per week practicing yoga, including in class and outside of class, assessed weekly via interview
Outcome measures
| Measure |
No Video/No One-on-One/No Text/No Incentive
n=12 Participants
This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes
|
No Video/No One-on-One/No Text/Yes Incentive
n=12 Participants
This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, but DOES receive financial Incentives to attend yoga classes
|
No Video/No One-on-One/Yes Text/No Incentive
n=12 Participants
This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or financial Incentives to attend yoga classes, but DOES receive prompting Text messages
|
No Video/No One-on-One/Yes Text/Yes Incentive
n=12 Participants
This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, but DOES receive prompting Text messages and financial Incentives to attend yoga classes
|
No Video/Yes One-on-One/No Text/No Incentive
n=12 Participants
This group does not receive Personal Practice Videos or prompting Text messages or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor
|
No Video/Yes One-on-One/No Text/Yes Incentive
n=12 Participants
This group does not receive Personal Practice Videos or prompting Text messages, but DOES receive One-on-One individual sessions with a Yoga Instructor, and financial Incentives to attend yoga classes
|
No Video/Yes One-on-One/Yes Text/No Incentive
n=12 Participants
This group does not receive Personal Practice Videos or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor and prompting Text messages
|
No Video/Yes One-on-One/Yes Text/Yes Incentive
n=12 Participants
This group does not receive Personal Practice Videos, but DOES receive One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
|
Yes Video/No One-on-One/No Text/No Incentive
n=12 Participants
This group does not receive One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos
|
Yes Video/No One-on-One/No Text/Yes Incentive
n=12 Participants
This group does not receive One-on-One individual sessions with a Yoga Instructor or prompting Text messages, but DOES receive Personal Practice Videos and financial Incentives to attend yoga classes
|
Yes Video/No One-on-One/Yes Text/No Incentive
n=12 Participants
This group does not receive One-on-One individual sessions with a Yoga Instructor or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos and prompting Text messages
|
Yes Video/No One-on-One/Yes Text/Yes Incentive
n=12 Participants
This group does not receive One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos, prompting Text messages, and financial Incentives to attend yoga classes
|
Yes Video/Yes One-on-One/No Text/No Incentive
n=12 Participants
This group does not receive prompting Text messages or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos and One-on-One individual sessions with a Yoga Instructor
|
Yes Video/Yes One-on-One/No Text/Yes Incentive
n=12 Participants
This group does not receive prompting Text messages, but DOES receive Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, and financial Incentives to attend yoga classes
|
Yes Video/Yes One-on-One/Yes Text/No Incentive
n=12 Participants
This group does not receive financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor and prompting Text messages
|
Yes Video/Yes One-on-One/Yes Text/Yes Incentive
n=12 Participants
This group receives Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Yoga Dosage
|
164.5 Total yoga Minutes
Interval 100.2 to 228.8
|
99.4 Total yoga Minutes
Interval 67.4 to 131.5
|
139.1 Total yoga Minutes
Interval 108.8 to 169.4
|
102.2 Total yoga Minutes
Interval 72.2 to 132.1
|
116.6 Total yoga Minutes
Interval 73.9 to 159.3
|
154.8 Total yoga Minutes
Interval 113.8 to 195.8
|
84.5 Total yoga Minutes
Interval 68.5 to 100.6
|
185.6 Total yoga Minutes
Interval 118.9 to 252.4
|
89.7 Total yoga Minutes
Interval 72.6 to 106.8
|
90.9 Total yoga Minutes
Interval 68.5 to 113.4
|
111.4 Total yoga Minutes
Interval 67.0 to 155.7
|
122.3 Total yoga Minutes
Interval 98.1 to 146.4
|
145.8 Total yoga Minutes
Interval 99.6 to 192.0
|
144.9 Total yoga Minutes
Interval 116.6 to 173.1
|
167.0 Total yoga Minutes
Interval 129.1 to 204.8
|
117.2 Total yoga Minutes
Interval 83.0 to 151.4
|
Adverse Events
No Video/No One-on-One/No Text/No Incentive
Serious events: 4 serious events
Other events: 9 other events
Deaths: 0 deaths
No Video/No One-on-One/No Text/Yes Incentive
Serious events: 3 serious events
Other events: 9 other events
Deaths: 0 deaths
No Video/No One-on-One/Yes Text/No Incentive
Serious events: 3 serious events
Other events: 6 other events
Deaths: 0 deaths
No Video/No One-on-One/Yes Text/Yes Incentive
Serious events: 2 serious events
Other events: 7 other events
Deaths: 0 deaths
No Video/Yes One-on-One/No Text/No Incentive
Serious events: 3 serious events
Other events: 5 other events
Deaths: 0 deaths
No Video/Yes One-on-One/No Text/Yes Incentive
Serious events: 1 serious events
Other events: 8 other events
Deaths: 0 deaths
No Video/Yes One-on-One/Yes Text/No Incentive
Serious events: 2 serious events
Other events: 10 other events
Deaths: 0 deaths
No Video/Yes One-on-One/Yes Text/Yes Incentive
Serious events: 1 serious events
Other events: 5 other events
Deaths: 0 deaths
Yes Video/No One-on-One/No Text/No Incentive
Serious events: 2 serious events
Other events: 8 other events
Deaths: 0 deaths
Yes Video/No One-on-One/No Text/Yes Incentive
Serious events: 1 serious events
Other events: 9 other events
Deaths: 0 deaths
Yes Video/No One-on-One/Yes Text/No Incentive
Serious events: 2 serious events
Other events: 7 other events
Deaths: 0 deaths
Yes Video/No One-on-One/Yes Text/Yes Incentive
Serious events: 4 serious events
Other events: 8 other events
Deaths: 0 deaths
Yes Video/Yes One-on-One/No Text/No Incentive
Serious events: 1 serious events
Other events: 8 other events
Deaths: 0 deaths
Yes Video/Yes One-on-One/No Text/Yes Incentive
Serious events: 1 serious events
Other events: 6 other events
Deaths: 0 deaths
Yes Video/Yes One-on-One/Yes Text/No Incentive
Serious events: 3 serious events
Other events: 7 other events
Deaths: 0 deaths
Yes Video/Yes One-on-One/Yes Text/Yes Incentive
Serious events: 1 serious events
Other events: 8 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
No Video/No One-on-One/No Text/No Incentive
n=12 participants at risk
This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes
|
No Video/No One-on-One/No Text/Yes Incentive
n=12 participants at risk
This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, but DOES receive financial Incentives to attend yoga classes
|
No Video/No One-on-One/Yes Text/No Incentive
n=12 participants at risk
This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or financial Incentives to attend yoga classes, but DOES receive prompting Text messages
|
No Video/No One-on-One/Yes Text/Yes Incentive
n=12 participants at risk
This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, but DOES receive prompting Text messages and financial Incentives to attend yoga classes
|
No Video/Yes One-on-One/No Text/No Incentive
n=12 participants at risk
This group does not receive Personal Practice Videos or prompting Text messages or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor
|
No Video/Yes One-on-One/No Text/Yes Incentive
n=12 participants at risk
This group does not receive Personal Practice Videos or prompting Text messages, but DOES receive One-on-One individual sessions with a Yoga Instructor, and financial Incentives to attend yoga classes
|
No Video/Yes One-on-One/Yes Text/No Incentive
n=12 participants at risk
This group does not receive Personal Practice Videos or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor and prompting Text messages
|
No Video/Yes One-on-One/Yes Text/Yes Incentive
n=12 participants at risk
This group does not receive Personal Practice Videos, but DOES receive One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
|
Yes Video/No One-on-One/No Text/No Incentive
n=12 participants at risk
This group does not receive One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos
|
Yes Video/No One-on-One/No Text/Yes Incentive
n=12 participants at risk
This group does not receive One-on-One individual sessions with a Yoga Instructor or prompting Text messages, but DOES receive Personal Practice Videos and financial Incentives to attend yoga classes
|
Yes Video/No One-on-One/Yes Text/No Incentive
n=12 participants at risk
This group does not receive One-on-One individual sessions with a Yoga Instructor or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos and prompting Text messages
|
Yes Video/No One-on-One/Yes Text/Yes Incentive
n=12 participants at risk
This group does not receive One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos, prompting Text messages, and financial Incentives to attend yoga classes
|
Yes Video/Yes One-on-One/No Text/No Incentive
n=12 participants at risk
This group does not receive prompting Text messages or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos and One-on-One individual sessions with a Yoga Instructor
|
Yes Video/Yes One-on-One/No Text/Yes Incentive
n=12 participants at risk
This group does not receive prompting Text messages, but DOES receive Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, and financial Incentives to attend yoga classes
|
Yes Video/Yes One-on-One/Yes Text/No Incentive
n=12 participants at risk
This group does not receive financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor and prompting Text messages
|
Yes Video/Yes One-on-One/Yes Text/Yes Incentive
n=12 participants at risk
This group receives Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Psychiatric disorders
Anxiety
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
General disorders
Flu-like symptoms
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Injury, poisoning and procedural complications
Fracture
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Gastrointestinal disorders
Gastric ulcer
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
General disorders
General disorders - Other, specify
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Cardiac disorders
Heart failure
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Metabolism and nutrition disorders
Hyperglycemia
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Blood and lymphatic system disorders
Anemia
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
General disorders
Injection site reaction
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Infections and infestations
Lung infection
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Cardiac disorders
Myocardial Infarction
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Psychiatric disorders
Psychiatric Disorders- Other, Specify
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Renal and urinary disorders
Renal calculi
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Nervous system disorders
Seizure
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Infections and infestations
Skin infection
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Social circumstances
Social circumstances - Other, specify
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Psychiatric disorders
Suicidal ideation
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Surgical and medical procedures
Surgical and medical procedures - Other, specify
|
16.7%
2/12 • Number of events 2 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Infections and infestations
Infections and infestations - Other, specify
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Nervous system disorders
Syncope
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Infections and infestations
Upper respiratory infection
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Injury, poisoning and procedural complications
Injury, poisoning and procedural complications - Other, specify
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
Other adverse events
| Measure |
No Video/No One-on-One/No Text/No Incentive
n=12 participants at risk
This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes
|
No Video/No One-on-One/No Text/Yes Incentive
n=12 participants at risk
This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, but DOES receive financial Incentives to attend yoga classes
|
No Video/No One-on-One/Yes Text/No Incentive
n=12 participants at risk
This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or financial Incentives to attend yoga classes, but DOES receive prompting Text messages
|
No Video/No One-on-One/Yes Text/Yes Incentive
n=12 participants at risk
This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, but DOES receive prompting Text messages and financial Incentives to attend yoga classes
|
No Video/Yes One-on-One/No Text/No Incentive
n=12 participants at risk
This group does not receive Personal Practice Videos or prompting Text messages or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor
|
No Video/Yes One-on-One/No Text/Yes Incentive
n=12 participants at risk
This group does not receive Personal Practice Videos or prompting Text messages, but DOES receive One-on-One individual sessions with a Yoga Instructor, and financial Incentives to attend yoga classes
|
No Video/Yes One-on-One/Yes Text/No Incentive
n=12 participants at risk
This group does not receive Personal Practice Videos or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor and prompting Text messages
|
No Video/Yes One-on-One/Yes Text/Yes Incentive
n=12 participants at risk
This group does not receive Personal Practice Videos, but DOES receive One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
|
Yes Video/No One-on-One/No Text/No Incentive
n=12 participants at risk
This group does not receive One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos
|
Yes Video/No One-on-One/No Text/Yes Incentive
n=12 participants at risk
This group does not receive One-on-One individual sessions with a Yoga Instructor or prompting Text messages, but DOES receive Personal Practice Videos and financial Incentives to attend yoga classes
|
Yes Video/No One-on-One/Yes Text/No Incentive
n=12 participants at risk
This group does not receive One-on-One individual sessions with a Yoga Instructor or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos and prompting Text messages
|
Yes Video/No One-on-One/Yes Text/Yes Incentive
n=12 participants at risk
This group does not receive One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos, prompting Text messages, and financial Incentives to attend yoga classes
|
Yes Video/Yes One-on-One/No Text/No Incentive
n=12 participants at risk
This group does not receive prompting Text messages or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos and One-on-One individual sessions with a Yoga Instructor
|
Yes Video/Yes One-on-One/No Text/Yes Incentive
n=12 participants at risk
This group does not receive prompting Text messages, but DOES receive Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, and financial Incentives to attend yoga classes
|
Yes Video/Yes One-on-One/Yes Text/No Incentive
n=12 participants at risk
This group does not receive financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor and prompting Text messages
|
Yes Video/Yes One-on-One/Yes Text/Yes Incentive
n=12 participants at risk
This group receives Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Psychiatric disorders
Depression
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
16.7%
2/12 • Number of events 2 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
General disorders
Edema limbs
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Endocrine disorders
Endocrine disorders - Other, specify
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
General disorders
Fatigue
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
General disorders
Fever
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
General disorders
Flu-like symptoms
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Injury, poisoning and procedural complications
Fracture
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
General disorders
General disorders - Other, specify
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
General disorders
Generalized edema
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Nervous system disorders
Headache
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
16.7%
2/12 • Number of events 2 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Vascular disorders
Hypertension
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Infections and infestations
Lung infection
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Infections and infestations
Infections and infestations - Other, specify
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
General disorders
Injection site reaction
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Infections and infestations
Kidney infection
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
16.7%
2/12 • Number of events 2 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Psychiatric disorders
Psychiatric Disorders- Other, Specify
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Nervous system disorders
Seizure
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Nervous system disorders
Nervous system disorders - Other, specify
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
General disorders
Non-cardiac chest pain
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Gastrointestinal disorders
Oral pain
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
General disorders
Pain
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Infections and infestations
Sinusitis
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Cardiac disorders
Palpitations
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Musculoskeletal and connective tissue disorders
Muscle cramp
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Infections and infestations
Skin infection
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Respiratory, thoracic and mediastinal disorders
Sore throat
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Surgical and medical procedures
Surgical and medical procedures - Other, specify
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
16.7%
2/12 • Number of events 2 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
16.7%
2/12 • Number of events 2 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Infections and infestations
Upper respiratory infection
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
16.7%
2/12 • Number of events 2 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Gastrointestinal disorders
Abdominal pain
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Injury, poisoning and procedural complications
Injury, poisoning and procedural complications - Other, specify
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal and connective tissue disorder - Other, specify
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
8.3%
1/12 • Number of events 1 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
0.00%
0/12 • 12 months
We inquired about adverse events at 3 months, 6 months, and 12 months.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place